Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 534

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer

Shin, Daiha, Kim, Eun Hye, Lee, Jaewang, Roh, Jong-Lyel·2018·Free Radical Biology and Medicine

Abstract

&NA; Glutathione peroxidase 4 (GPX4) is a regulator of ferroptosis (iron‐dependent, non‐apoptotic cell death); its inhibition can render therapy‐resistant cancer cells susceptible to ferroptosis. However, some cancer cells develop mechanisms protective against ferroptosis; understanding these mechanisms could help overcome chemoresistance. In this study, we investigated the molecular mechanisms underlying resistance to ferroptosis induced by GPX4 inhibition in head and neck cancer (HNC). The effects of two GPX4 inhibitors, (1S, 3R)‐RSL3 and ML‐162, and of trigonelline were tested in HNC cell lines, including cisplatin‐resistant (HN3R) and acquired RSL3‐resistant (HN3‐rslR) cells. The effects of the inhibitors and trigonelline, as well as of inhibition of the p62, Keap1, or Nrf2 genes, were assessed by cell viability, cell death, lipid ROS production, and protein expression, and in mouse tumor xenograft models. Treatment with RSL3 or ML‐162 induced the ferroptosis of HNC cells to varying degrees. RSL3 or ML‐162 treatment increased the expression of p62 and Nrf2 in chemoresistant HN3R and HN3‐rslR cells, inactivated Keap1, and increased expression of the phospho‐PERK–ATF4–SESN2 pathway. Transcriptional activation of Nrf2 was associated with resistance to ferroptosis. Overexpression of Nrf2 by inhibiting Keap1 or Nrf2 gene transfection rendered chemosensitive HN3 cells resistant to RSL3. However, Nrf2 inhibition or p62 silencing sensitized HN3R cells to RSL3. Trigonelline sensitized chemoresistant HNC cells to RSL3 treatment in a mouse model transplanted with HN3R. Thus, activation of the Nrf2–ARE pathway contributed to the resistance of HNC cells to GPX4 inhibition, and inhibition of this pathway reversed the resistance to ferroptosis in HNC. Graphical abstract A proposed model of Nrf2‐induced resistance to GPX4 inhibition‐induced ferroptosis in cancer cells. The GPX4 inhibitors RSL3 and ML‐162 induce endoplasmic reticulum stress and subsequently p62 expression via the PERK–ATF4–SESN2 pathways. Nrf2 is activated by p62–Keap1 interaction and antioxidant response elements (ARE) related to iron and antioxidant systems is increased, resulting in a decreased labile iron pool, thus contributing to the resistance to ferroptosis. Figure. No caption available. HighlightsRSL3 and ML‐162 inhibited GPX4, inducing the ferroptotic death of head and neck cancer (HNC) cells to varying degrees.Resistance to GPX4 inhibition is related to the increased expression of p62.The p62–Keap1–Nrf2 antioxidant system is also involved in the RSL3 resistance mechanism.Nrf2 inhibition sensitized chemoresistant HNC cells to RSL3 treatment.Trigonelline reversed RSL3‐induced resistance to ferroptosis in HNC via inhibition of the Nrf2 system, both in vitro and in vivo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.freeradbiomed.2018.10.426

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 534

Metadata

Authors
Shin, D., Kim, E. H., Lee, J., & Roh, J.-L.
Venue
Free Radical Biology and Medicine
Publisher
Elsevier BV
Published
2018-12
Volume
129
Pages
454-462
ISSN
0891-5849 (ISSN-L)
OpenAlex
W2897111276
Cited by
534
References
17
FWCI
24.18
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. https://app.cochat.ai/papers/10.1016/j.freeradbiomed.2018.10.426
The paper
Shin, D., Kim, E. H., Lee, J., & Roh, J.-L. (2018). Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Free Radical Biology and Medicine. https://doi.org/10.1016/j.freeradbiomed.2018.10.426

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.